Skip to the record

Swiss capital increases, read from the official gazette and scored for financing rounds.

updated every weekdayrelease r10data as of 8 Oct 2026

↺ Try a rewind: Soverli AG on 24 Sep 2025, 83 days before the round was announced

Release evaluation · 7 Oct 2026 · does not rewind · rules + Claude: precision 2%–100% (n=17), recall 16/30 announced rounds · rules-only: precision 1%–99% (n=29), recall 18/30 announced rounds · Methodology

Published by 3 May 2026

Drag the red line through time · ← → a day · Shift+← → a week. Later days aren’t drawn: they haven’t been published yet.

Scope · likely financings by canton

43 likely financings · 4 Apr 2026 – 3 May 2026 · the feed below shows one weekBS ✕ show all cantonsMap: Natural Earth

Likely financing: Looks like new money from outside investors: Claude, reading the entry and the rule signals, scores it 0.60 or higher.
Undecided: Some financing signals, not enough to call it: a score from 0.35 to below 0.60, or no usable score.
Capital increased: No sign of a financing round: the pre-filter found nothing to send to Claude, or Claude scored it below 0.35. Typical causes are converted loans, assets contributed in kind, reserves turned into capital or a conversion to an AG.
Confirmed round: A financing announcement on startupticker.ch names the company and matches this increase.

Published 27 Apr – 3 May 2026 · canton BS

4 capital increases · 2 shown

Capital increases published 27 Apr – 3 May 2026
Company	Status	Nominal share capital (CHF) before → after	New shares, % of post-step shares	Announced roundnot disclosed in the SHAB	SHAB published	Source
BioCopy AGBS · Die Gesellschaft bezweckt die (auch softwaregestützte) Identifizierung, Entwicklung, Herstellung, Vermarktung …SHAB publication HR02-1006640409	Likely financing · possible confirmationscore 0.72	228’221.14 → 260’377.34New shares 12.3%	12.3%	—	1 May 2026	SHAB publication HR02-1006640409
RhyGaze AGBS · Zweck der Gesellschaft ist die Forschung, Entwicklung, die Produktion und der Vertrieb von pharmazeutischen …SHAB publication HR02-1006639100	Likely financingscore 0.90	649’057.80 → 975’393.05New shares 33.5%	33.5%	—	30 Apr 2026	SHAB publication HR02-1006639100

2 other capital increases published this week ▸